Addex therapeutics reports full year 2023 financial results and provides corporate update

Top-line data from adx71149 phase 2 epilepsy study expected by mid-may 2024 launched neurosterix with perceptive advisors, raising usd 63 million in series a to accelerate development of preclinical portfolio received chf 5 million upfront and 20% equity in neurosterix, providing cash runway beyond 2026 ad hoc announcement pursuant to art. 53 lr geneva, switzerland, april 18, 2024 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year 2023 financial results for the period ended december 31, 2023 and provided a corporate update.
ADXN Ratings Summary
ADXN Quant Ranking